nofunanymore
Posted - 6 hours ago
$RXRX $EXAI lol
sogenerous
Posted - 7 hours ago
$RXRX and $EXAI 2 shitcos combine. $RXRX the slow painful bleedout to 2-4 has begun will be painful and suck life out of longs now on this as range breaks. I will be buying much much lower from here - no position yet going lower
briefingcom
Posted - 1 day ago
$RXRX: Recursion Pharmaceuticals and and Exscientia ($EXAI) have officially combined to advance the industrialization of drug discovery https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20241120070844RXRX&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
G101SPM
Posted - 1 day ago
$RXRX $6.39 bid. DAC (dollar average cost) $6.50 (8.8.24). EXIT $10.00. RETAIN POSITION. UPDATE: The business combination of Recursion and Exscientia has been completed, with Exscientia becoming a wholly owned subsidiary of Recursion creating a vertically-integrated and technology-enabled drug discovery platform. Exscientia ADSs (Nasdaq: $EXAI) ceased trading and will be delisted from Nasdaq. “I believe the combination of the incredible teams and platforms at Exscientia and Recursion position us as the leader of the AI-enabled drug discovery and development space,” said Chris Gibson, Ph.D., Co-Founder and CEO of Recursion. “With more than 10 clinical and preclinical programs in the internal pipeline, more than 10 partnered programs and over $450M in upfront and realized milestone payments received from partners to date out of more than $20B possible, we are advancing a flywheel of discovery and creating value in our pipeline through technology.”
tradingcalendar
Posted - 2 days ago
M&A Exscientia Plc $EXAI to merge with Recursion Pharmaceuticals $RXRX - EXAI shareholders to receive 0.7729 shares of RXRX for every share of Exscientia owned - Shares of EXAI are expected to be delisted after the close of extended hours trading, on November 19th More Information : https://www.sec.gov/Archives/edgar/data/1865408/000110465924107445/tm2424015d6_ex99-1.htm
WangSLO
Posted - 6 days ago
$RXRX $EXAI the short shares also get converted... Do the days to cover also get converted? Does that make this 21 days to cover ? 🤣
WangSLO
Posted - 6 days ago
$RXRX And so is the company that's merging in $EXAI
glenwoodnate
Posted - 6 days ago
@iriepett I think it's a mixed bag. $RXRX and $EXAI were both focused on areas of medicine that are genetic, cancerous, or rare, mostly with low prevalence. It's uncontroversial that we should have treatments for those diseases. If he makes it easier to get from IND to market, or forces big pharma to give more royalties to biotech, that's a net positive. Nobody will be throwing more compounds with more ADMET data more quickly than AI-based drug discovery. If he makes it harder to get from IND to market, which is more likely, or cripples big pharma to the point where it can't pay out milestones, that's a net negative. I suspect he's a net neutral, if he's approved. You take the good with the bad...
glenwoodnate
Posted - 6 days ago
@Myman2 Nothing at all. Zero involvement. That goes for $EXAI as well.
Villidj_Idjit
Posted - 1 week ago
$EXAI One to put on your watchlist.
WangSLO
Posted - 1 week ago
@Skipper777 I do actually think the shares of $EXAI are added to $RXRX when the merger closes. Which is around 99M/.77 since that's the EXAI float / conversion rate. However what I find out of the ordinary is that they're having a shareholder meeting on the 20th before the market open, once the merger completes. At this point in time, we know everything we need to know about the merger so why have an extra shareholder meeting on the 20th before market open? I think they're going to announce something big, that's going to make the stock run hard. Bad news is typically announced after the market close on a Friday. But we get news on Wednesday before market open. Let's see where this goes.
WangSLO
Posted - 1 week ago
I can't tell if $EXAI is following $RXRX or if it's vise versa l
WangSLO
Posted - 1 week ago
$EXAI $RXRX
RocroBio
Posted - 1 week ago
$EXAI
WangSLO
Posted - 1 week ago
Both $RXRX and $EXAI are shorted, going into this merger. Coupled with a shareholder update meeting on 11/20 BEFORE market open ... Yeah I think some people are trapped lmao
WangSLO
Posted - 1 week ago
@sprez87 I believe it's an all stock transaction, if you own $EXAI You'll just wake up one morning and it will say "RXRX"
glenwoodnate
Posted - 1 week ago
$RXRX $EXAI Exscientia Plc announced that its shareholders have overwhelmingly approved a significant resolution at a recent Court Meeting, with 98.11% of votes in favor of the proposed scheme.
Mergerbrief
Posted - 1 week ago
$EXAI / $RXRX - Shareholder Votes $EXAI, $RXRX MergerBrief.com Sign Up For Full Schedule
WangSLO
Posted - 1 week ago
$EXAI $RXRX I can't find earnings anywhere, I thought they reported today. In either case, it's up higher per Robinhood . Must have been positive
alteralgo
Posted - 1 week ago
@WangSLO Yep all shares held in $EXAI get converted to 0.7729 shares of $RXRX
glenwoodnate
Posted - 1 week ago
$RXRX $EXAI After Recursion broke above $7.00, there have been repeated large block sales. $7.00 has turned from resistance to support. Volumes are amazingly high for this early in the morning. Bears are fighting tooth and nail to prevent the stock from rising, but it seems the cavalry has plenty of ammo.
WangSLO
Posted - 2 weeks ago
$EXAI $RXRX
WangSLO
Posted - 2 weeks ago
$EXAI when this merges with rxrx, doesn't that mean that holders of this ADR need to convert all their shares to shares of RXRX, and also where are these shares coming from? The exchange? What happens if there aren't enough floating shares? Do shorts have to come up with the shares that they shorted ? (Meaning they buy them aka cover?)
RocroBio
Posted - 2 weeks ago
$EXAI
vu_jade
Posted - 2 weeks ago
$RXRX $EXAI artificial intelligence in the biopharma Space could be a game changer .. these two will lead the charge
glenwoodnate
Posted - 10/30/24
$RXRX $EXAI Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th Company plans to host update call on Nov 20, 2024 after the anticipated close of the proposed business combination with Exscientia SALT LAKE CITY, Oct. 29, 2024 -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide business updates and report its Q3 2024 financial results on Wednesday, Nov 6, 2024, following the close of the financial markets. The company will not host its normal L(earnings) Call in relation to the business updates and financials for the third quarter. Instead, the company expects to host an update call after the anticipated close of the proposed business combination with Exscientia, which is expected to be on Nov 20, 2024. We will broadcast the live stream from Recursion’s X (formerly Twitter), LinkedIn and YouTube accounts. https://www.sec.gov/Archives/edgar/data/1601830/000160183024000184/recursion-solicitationmate.htm
Deoyesconsult
Posted - 10/30/24
$EXAI Zodiac Signs to Win the Jackpot on November 1st, 2024! New Super Moon https://youtu.be/Uroyg4s7JAU?si=S4PdQU9MSUgUpX0T
vu_jade
Posted - 10/29/24
$EXAI $rXRX I bought more .. merge these mothers
Quantumup
Posted - 10/27/24
BofA $CRSP, $DAWN, $EDIT, $ERAS, $EXAI
glenwoodnate
Posted - 10/22/24
$RXRX The platform and the pipeline look no less impressive than they did two days ago. Today marked the first Phase 2 dosing of REC-3964. This small molecule selectively targets and degrades the toxin produced by C. difficile, which has a whole host of benefits over attacking the bacterium. REC-994 met its primary safety Phase 2 trial endpoint. Positive MRI trends. Could've just been underdosed. The CDK7 inhibitor from the merger with $EXAI is extremely promising. CDK7 phosphorylates the CTD of Pol II, CDK9, and other cell cycle kinases (CDK1, CDK2, CDK4, and CDK6). REC-1245 is a selective RBM39 degrader, which will likely be much less toxic than current CDK12/13 therapies. Just can't get out of the shorts' crosshairs, and rising 10Y yields don't help...